Resumen
Microsatellite stable colorectal cancer represents the majority of patients who have been diagnosed with colorectal cancer, and it is inherently resistant to currently available immunotherapy. After standard-of-care chemotherapy, patients have very limited remaining treatment options. Therefore, defining innovative approaches to reactivate the immune system is critical, and novel treatments are desperately needed. Here, we review and highlight a key immune cell that is involved in reprogramming the immune system in colorectal cancer called the myeloid-derived suppressor cell. The successful targeting of myeloid-derived suppressor cells with novel drug combinations in clinical trials may allow for microsatellite stable colorectal cancer to become responsive to immunotherapy and thereby improve patients? outcomes.